Paris, 3 May 2012 – NYSE Euronext today announced the listing on NYSE Alternext in Paris of Vexim, a key player in innovative microsurgery for spinal trauma.
Founded in 2006 and based in Toulouse, Vexim specialises in minimally invasive treatment of vertebral compression fractures and has designed and developed SpineJack®, which it markets. This innovative technology consists of a 5-mm titanium implant that restores the crushed vertebrae’s initial height, volume and natural anatomy, and eliminates pain. The company currently employs 27 people and has an extensive distribution network in France and Germany.
Vexim (ticker code: ALVXM) was listed through admission to trading of 2,163,100 existing shares and 1,158,544 new shares issued under a Global Offering.The Global Offering raised a total of €11 million.
The admission and issue price of Vexim shares was set at €9.50. Market capitalization stood at around €31.6 million on the day of listing.
“We are delighted to welcome Toulouse-based Vexim to NYSE Alternext. Listing is a new an important stage in its growth that will consolidate its reputation and raise the funds it needs to pursue investment in R&D,” said Marc Lefèvre, Head of European Coverage at NYSE Euronext. “NYSE Alternext is a perfect match for companies like Vexim that want to benefit from our European reach which attracts a rising number of investors and higher liquidity.”
Vincent Gardès, CEO of Vexim, added: “We would like to thank all of the shareholders that have placed their trust in us and made this critical step a success, and who are now on board as we pursue our commercial development.”
In seven years, €2.7 billion has been raised on NYSE Alternext, half through secondary issues, by companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their market capitalisation totals €6.2 billion. Today 183 companies are listed on NYSE Alternext.
The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.